1. CDC . History of measles. Centers for Disease Control and Prevention. Published November 5, 2020. Accessed June 2021. https://www.cdc.gov/measles/about/history.html
Google Scholar2. World Health Organization . Measles. 2019. Accessed June 2021. https://www.who.int/news-room/fact-sheets/detail/measles
Google Scholar3. Garg, RK, Mahadevan, A, Malhotra, HS, Rizvi, I, Kumar, N, Uniyal, R. Subacute sclerosing panencephalitis. Rev Med Virol. 2019;29:e2058. doi:10.1002/rmv.2058
Google Scholar | Crossref | Medline4. Horta-Barbosa, L, Fuccillo, DA, London, WT, Jabbour, JT, Zeman, W, Sever, JL. Isolation of measles virus from brain cell cultures of two patients with subacute sclerosing panencephalitis. Proc Soc Exp Biol Med. 1969;132:272-277. doi:10.3181/00379727-132-34196
Google Scholar | SAGE Journals | ISI5. Payne, FE, Baublis, JV, Itabashi, HH. Isolation of measles virus from cell cultures of brain from a patient with subacute sclerosing panencephalitis. N Engl J Med. 1969; 281:585-589. doi:10.1056/NEJM196909112811103
Google Scholar | Crossref | Medline | ISI6. Dawson, JR . Cellular inclusions in cerebral lesions of lethargic encephalitis. Am J Pathol. 1933;9:7-16.3.
Google Scholar7. Dawson, JR . Cellular inclusions in cerebral lesions of epidemic encephalitis. Arch Neurol Psychiatry. 1934;31:685-700.
Google Scholar | Crossref8. Kija, E, Ndondo, A, Spittal, G, Hardie, DR, Eley, B, Wilmshurst, JM. Subacute sclerosing panencephalitis in South African children following the measles outbreak between. 2009;2011:713-718. doi:10.7196/SAMJnew.7788
Google Scholar | Crossref9. Wendorf, KA, Winter, K, Zipprich, J, et al. Subacute sclerosing panencephalitis: the devastating measles complication that might be more common than previously estimated. Clin Infect Dis. 2017;65:226-232. doi:10.1093/cid/cix302
Google Scholar | Crossref | Medline10. Prashanth, LK, Taly, AB, Ravi, V, Sinha, S, Arunodaya, GR. Adult onset subacute sclerosing panencephalitis: clinical profile of 39 patients from a tertiary care centre. J Neurol Neurosurg Psychiatry. 2006;77:630-633. doi:10.1136/jnnp.2005.085829
Google Scholar | Crossref | Medline11. PeBenito, R, Naqvi, SH, Arca, MM, Schubert, R. Fulminating subacute sclerosing panencephalitis: case report and literature review. Clin Pediatr. 1997;36:149-154. doi:10.1177/000992289703600306
Google Scholar | SAGE Journals | ISI12. Sudfeld, CR, Navar, AM, Halsey, NA. Effectiveness of measles vaccination and vitamin a treatment. Internet J Epidemiol. 2010;39(Suppl 1):i48-i55. doi:10.1093/ije/dyq021
Google Scholar | Crossref | Medline13. Institute of Medicine (US) . Immunization Safety Review Committee: Immunization Safety Review: Vaccines and Autism. National Academies Press; 2004.
Google Scholar14. CDC . MMR vaccine safety studies. Published June 8, 2020. https://www.cdc.gov/vaccinesafety/vaccines/mmr/mmr-studies.html.
Google Scholar15. Kannan, L, Garg, SK, Arya, R, Sankar, MJ, Anand, V. Treatments for subacute sclerosing panencephalitis. Cochrane Database Syst Rev. 2013;12:CD010867. doi:10.1002/14651858.CD010867
Google Scholar | Crossref16. World Health Organization . Measles – number of reported cases. Accessed July 29, 2021. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/measles—number-of-reported-cases
Google Scholar17. World Health Organization . Accessed June 2021. http://www.who.int/vaccine_safety/committee/reports/wer8102.pdf?ua=1
Google Scholar18. Mishra, B, Kakkar, N, Ratho, RK, Singhi, P, Prabhakar, S. Changing trend of SSPE over a period of ten years. Indian J Public Health. 2005;49:235-237.
Google Scholar | Medline19. Sonia, M, Lalit, D, Shobha, B, et al. Subacute sclerosing panencephalitis in a tertiary care centre in post measles vaccination era. J Commun Disord. 2009;41:161-167.
Google Scholar20. Ibrahim, SH, Amjad, N, Saleem, AF, Chand, P, Rafique, A, Humayun, KN. The upsurge of SSPE—a reflection of national measles immunization status in Pakistan. J Trop Pediatr. 2014;60:449-453. doi:10.1093/tropej/fmu050
Google Scholar | Crossref | Medline21. Hashimoto, K, Hosoya, M. Advances in antiviral therapy for subacute sclerosing panencephalitis. Molecules. 2021;26:427-2021. doi:10.3390/molecules26020427
Google Scholar | Crossref22. Zilber, N, Kahana, E. Environmental risk factors for subacute sclerosing panencephalitis (SSPE). Acta Neurol Scand. 1998;98:49-54. doi:10.1111/j.1600-0404.1998.tb07377.x
Google Scholar | Crossref | Medline23. Schönberger, K, Ludwig, MS, Wildner, M, Weissbrich, B. Epidemiology of subacute sclerosing panencephalitis (SSPE) in Germany from 2003 to 2009: a risk estimation. PLoS One. 2013;8:e68909. doi:10.1371/journal.pone.0068909
Google Scholar | Crossref | Medline24. Gadoth, N . Subacute sclerosing panencephalitis (SSPE) the story of a vanishing disease. Brain Dev. 2012;34:705-711. doi:10.1016/j.braindev.2011.12.008
Google Scholar | Crossref | Medline | ISI25. Mekki, M, Eley, B, Hardie, D, Wilmshurst, JM. Subacute sclerosing panencephalitis: clinical phenotype, epidemiology, and preventive interventions. Dev Med Child Neurol. 2019;61:1139-1144. doi:10.1111/dmcn.14166
Google Scholar | Crossref | Medline26. Rota, PA, Moss, WJ, Takeda, M, de Swart, RL, Thompson, KM, Goodson, JL. Measles. Nat Rev Dis Primers. 2016;2:16049. doi:10.1038/nrdp.2016.49
Google Scholar | Crossref | Medline27. Bale, JF Measles, mumps, rubella, and human parvovirus B19 infections and neurologic disease. Handb Clin Neurol. 2014;121:1345-1353. doi:10.1016/B978-0-7020-4088-7.00091-2
Google Scholar | Crossref | Medline28. Hosoya, M, Mori, S, Tomoda, A, et al. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob Agents Chemother. 2004;48:4631-4635. doi:10.1128/AAC.48.12.4631-4635.2004
Google Scholar | Crossref | Medline29. Ferren, M, Horvat, B, Mathieu, C. Measles encephalitis: towards new therapeutics. Viruses. 2019;11:1017-2019. doi:10.3390/v11111017
Google Scholar | Crossref30. Haspolat, S, Anlar, B, Köse, G, Coskun, M, Yegin, O. Interleukin-1beta, interleukin-1 receptor antagonist levels in patients with subacute sclerosing panencephalitis and the effects of different treatment protocols. J Child Neurol. 2001;16:417-420. doi:10.1177/088307380101600606
Google Scholar | SAGE Journals | ISI31. Sobczyk, W, Piłkowska, E, Iwińska-Buksowicz, B. Ocena zastosowania antyneoplastonu AS2-1 w podostrym stwardniajacym zapaleniu mózgu [The evaluation of the use of antineoplaston AS2-1 treatment in subacute sclerosing panencephalitis]. Neurol Neurochir Pol. 1999;33:797-805.
Google Scholar | Medline32. Sobczyk, W, Piłkowska, E, Iwińska-Buksowicz, B, Jakubowska, T. Ocena bezpośrednich (wczesnych) wyników leczenia antyneoplastonem AS2-1 u chorych z podostrym stwardniajacym zapaleniem mózgu (SSPE) [Assessment of early treatment results with antineoplaston AS2-1 in subacute sclerosing panencephalitis]. Neurol Neurochir Pol. 1997;31:1147-1156.
Google Scholar | Medline33. Häusler, M, Aksoy, A, Alber, M, et al. A multinational survey on actual diagnostics and treatment of subacute sclerosing panencephalitis. Neuropediatrics. 2015;46: 377-384. doi:10.1055/s-0035-1564618
Google Scholar | Crossref | Medline34. Oncel, I, Sancar, M, Konuskan, B, et al. Aprepitant in the treatment of subacute sclerosing panencephalitis: a randomized, double-blind, placebo-controlled study. Pediatr Neurol. 2020;110:59-63. doi:10.1016/j.pediatrneurol.2020.05.009
Google Scholar | Crossref | Medline